Evidence map›Paper›PMID 41680771›Full record

ArticleBMC pulmonary medicine2026

A rare case of community-acquired necrotizing pneumonia in a patient treated with adalimumab therapy.

Branavan Ragunanthan, Bachar Botrus, Bibek Shrestha, Jason Kim, Hend Elsaghir, Caitlyn Hollingshead, Fadi Safi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Branavan RagunanthanDepartment of Medicine, Infectious Disease, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA. branavan.ragunanthan@UToledo.Edu.
Bachar BotrusDepartment of Medicine, Critical Care, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Bibek ShresthaDepartment of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Jason KimDepartment of Medicine, Infectious Disease, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Hend ElsaghirDepartment of Medicine, Infectious Disease, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Caitlyn HollingsheadDepartment of Medicine, Infectious Disease, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Fadi SafiDepartment of Medicine, Pulmonology and Critical Care, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNecrotizing pneumonia is a life-threatening complication of community-acquired pneumonia managed in an intensive care setting with a multitude of diagnostic modalities and numerous therapeutic interventions. Pseudomonas aeruginosa remains an extremely uncommon organism known to cause necrotizing pneumonia, and of the cases reported, are almost entirely found in immunocompromised hosts. CASE DETAILS: Here, we report a case of Pseudomonas aeruginosa community-acquired necrotizing pneumonia in a host receiving adalimumab therapy that ultimately was not able to be healed despite targeted antibiotics.

conclusionAdalimumab is known to immunosuppress patients and increase risk of tuberculosis and fungal disease, but have unclear associations with other infections. This case exemplifies a rare encounter of Pseudomonas aeruginosa necrotizing pneumonia in a patient on adalimumab therapy contracted through the community. Treatment of necrotizing pneumonia in patients on adalimumab therapy does not differ significantly from other cases of non-adalimumab associated necrotizing pneumonia.

Indexed as

AdalimumabCommunity-Acquired PneumoniaPneumonia, NecrotizingPseudomonas InfectionsAnti-Bacterial AgentsCommunity-Acquired InfectionsHumansImmunocompromised HostMalePseudomonas aeruginosaTomography, X-Ray ComputedAdalimumabAnti-Bacterial AgentsAdalimumabCommunity-acquired pneumoniaNecrotizing pneumoniaPseudomonas aeruginosa

Identifiers

PMID41680771
PMCPMC13005451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.